Abstract
Background When compliance with infection control recommendations is non-optimal, hospitals may play an important role in hepatitis C (HCV) transmission. However, few studies have analysed HCV acquisition risk based on detailed empirical data in order to identify high-risk patient profiles or transmission hotspots.
Methods We used data from a prospective cohort study conducted on 500 patients in the internal medicine and surgery departments of Ain Shams hospital (Cairo, Egypt). We first performed a sequence analysis to describe patient trajectory profiles. Second, we estimated each patient’s individual risk of HCV acquisition based on ward-specific prevalence and procedures undergone. We then identified within-hospital risk hotspots by computing ward-level risks. A beta regression model was used to highlight upon-admission factors linked to HCV acquisition risk. Finally, ward-focused and patient-focused strategies were assessed for their ability to reduce HCV infection risk.
Findings Sequence analysis identified 4 distinct patient profiles. The estimated HCV acquisition risk varied widely between patients and patient profiles. The risk was found to be higher in the internal medicine hospital compared to the surgery hospital (median: 0·188% IQR [0·142%-0·235%] vs. 0·043%, CI 95%: [0·036%-0·050%]). Upon-admission risk predictors included source of admission, age, reason for hospitalization, and history of anti-schistosomiasis treatment, injection and endoscopy. Patient-focused interventions were found to be most effective to reduce HCV infection risk.
Interpretation Our results might help reduce the risk of HCV acquisition during hospitalisation in Egypt by targeting enhanced control measures to ward-level transmission hotspots and to at-risk patients identified upon admission.
Funding INSERM-ANRS (France Recherche Nord and Sud Sida-HIV Hépatites)
Research in context
Evidence before this study
Evidence before this study We searched PubMed for articles published between Jan 1, 1990 and Jul 05, 2022, and focused on risk assessment of iatrogenic HCV transmission. We used “Hepatitis C”, “risk assessment”, “model”, “transmission”, “hospital” and “patients” as keywords. We found five risk assessment articles, the oldest published in 1999 and the most recent in 2012. All of these studies were conducted in countries with low HCV prevalence and were only focusing on HCV transmission from patients to healthcare workers. In addition, the risks estimated within these studies were based on limited observations and did not take into account the procedure-specific transmission risk.
Added value of this study
Added value of this study Our study presents a probabilistic risk assessment of HCV transmission to patients within an Egyptian hospital using detailed empirical data. Based on these results, at-risk patient profiles and transmission hotspots were identified. In addition, we simulated ward-focused and patient-focused interventions in order to estimate the efficacy of a better equipment handling on the overall risk of HCV infection. Patient-focused interventions, for instance dedicating sterilized single-use material, were often found to be more efficient than ward-focused ones. However, targeting wards might be financially, logistically and ethically more acceptable.
Implications of all the available evidence
Implications of all the available evidence Considering the promising though insufficient results and high costs of the Egyptian HCV elimination program, our results may help reduce HCV transmission at an hospital level. The score we built may be used upon admission to detect high risk patients. In addition, enhanced control measures in transmission hotspots may lead to an important risk reduction for hospitalized patients. Finally, this work could be extended to other bloodborne pathogens such as Hepatitis B or HIV.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by INSERM-ANRS (France Recherche Nord and Sud Sida-HIV Hepatites), grant number 12320 B115.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from the Institutional Review Board of the Faculty of Medicine of Ain Shams University and from the Sheffield University, School of Health and Related Research.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Contact information : Paul Henriot, Conservatoire national des arts et métiers (MESuRS Laboratory), 292 rue Saint-Martin, 75003, Paris. Email address: paul.henriot{at}lecnam.net
Data Availability
The data analysed in this study is available upon request only. Individual data requests may be sent to the Committee for biomedical research (CorC) of Institut Pasteur (Paris, France ; secr-CORC@pasteur.fr).
